Log in

IMMUTEP LTD/S Stock Forecast, Price & News

+0.04 (+2.27 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $1.80
50-Day Range
MA: $1.65
52-Week Range
Now: $1.80
Volume243,370 shs
Average Volume736,899 shs
Market Capitalization$70.20 million
P/E RatioN/A
Dividend YieldN/A
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMMP



Sales & Book Value

Annual Sales$4.92 million
Book Value$0.57 per share



Market Cap$70.20 million
Next Earnings DateN/A
OptionableNot Optionable
+0.04 (+2.27 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

IMMUTEP LTD/S (NASDAQ:IMMP) Frequently Asked Questions

How has IMMUTEP LTD/S's stock been impacted by COVID-19?

IMMUTEP LTD/S's stock was trading at $2.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMMP shares have decreased by 15.5% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of IMMUTEP LTD/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMUTEP LTD/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IMMUTEP LTD/S

What price target have analysts set for IMMP?

2 brokers have issued 12-month target prices for IMMUTEP LTD/S's shares. Their forecasts range from $2.00 to $2.00. On average, they expect IMMUTEP LTD/S's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for IMMUTEP LTD/S

Are investors shorting IMMUTEP LTD/S?

IMMUTEP LTD/S saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 423,900 shares, an increase of 35.9% from the August 31st total of 311,900 shares. Based on an average daily trading volume, of 1,430,000 shares, the days-to-cover ratio is currently 0.3 days.
View IMMUTEP LTD/S's Short Interest

Who are some of IMMUTEP LTD/S's key competitors?

What other stocks do shareholders of IMMUTEP LTD/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMMUTEP LTD/S investors own include CHF Solutions (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

Who are IMMUTEP LTD/S's key executives?

IMMUTEP LTD/S's management team includes the following people:
  • Mr. Marc Voigt, Exec. Director, CEO, CFO & Chief Bus. Officer (Age 46)
  • Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 42)
  • Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer (Age 64)
  • Mr. Jay R. Campbell, Chief Bus. Officer
  • Mr. David Fang, Fin. Director & Assistant Company Sec.

What is IMMUTEP LTD/S's stock symbol?

IMMUTEP LTD/S trades on the NASDAQ under the ticker symbol "IMMP."

How do I buy shares of IMMUTEP LTD/S?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMMUTEP LTD/S's stock price today?

One share of IMMP stock can currently be purchased for approximately $1.80.

How big of a company is IMMUTEP LTD/S?

IMMUTEP LTD/S has a market capitalization of $70.20 million and generates $4.92 million in revenue each year.

What is IMMUTEP LTD/S's official website?

The official website for IMMUTEP LTD/S is www.immutep.com.

How can I contact IMMUTEP LTD/S?

IMMUTEP LTD/S's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at 61-2-8315-7003 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.